查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1356527

非侵入性癌症诊断市场报告：2030 年趋势、预测与竞争分析

Non-Invasive Cancer Diagnostic Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

非侵入性癌症诊断的趋势和预测

预计到 2030 年，全球非侵入性癌症诊断市场将达到 1,992 亿美元，2024 年至 2030 年年复合成长率为 6.8%。该市场的主要促进因素是人们对慢性癌症的日益关注、先进的基于生物标誌物的检测方法的引入以及政府支持的促进非侵入性诊断测试使用的倡议。由于固体癌、血癌、肺癌和乳癌市场的商机，全球非侵入性癌症诊断市场的未来充满希望。

非侵入性癌症诊断市场洞察

  • 根据Lucintel的预测，临床化学由于其高灵敏度、低成本和广泛可用性等各种优势，预计将在预测期内实现最高成长。
  • 由于全球乳癌患者数量不断增加，乳癌仍然是最大的部分。
  • 由于其发达的医疗基础设施、癌症相关患者数量的增加以及主要企业的存在，预计北美在预测期内将出现最高的增长。

本报告回答了 11 个关键问题：

  • Q.1. 细分市场中最有前途和高成长的机会是什么？
  • Q.2.哪个细分市场将以更快的速度成长？为什么？
  • Q.3.您认为哪些地区未来会出现更快的成长？为什么？
  • Q.4. 影响市场动态的主要要素有哪些？市场的主要挑战和商业风险是什么？
  • Q.5. 这个市场的商业风险和竞争威胁是什么？
  • Q.6.这个市场有哪些新趋势？为什么？
  • Q.7.市场客户需求有何改变？
  • Q.8. 该市场有哪些新发展以及哪些公司处于领先地位？
  • Q.9.这个市场的主要企业有哪些？主要企业采取哪些策略配合措施来发展业务？
  • Q.10. 该市场上的竞争产品有哪些，由于材料或产品替代导致市场占有率下降的威胁有多大？
  • Q.11.过去年度发生了哪些併购事件，对产业产生了哪些影响？

目录

第1章执行摘要

第2章全球非侵入性癌症诊断市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业促进因素与挑战

第3章2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球非侵入性癌症诊断市场趋势（2018-2023）与预测（2024-2030）
  • 按治疗药物分類的全球非侵入性癌症诊断市场
    • 固态肿瘤
    • 血癌
    • 肺癌
    • 乳癌
    • 其他的
  • 按技术分類的全球非侵入性癌症诊断市场
    • 临床化学
    • 免疫化学
    • 分子诊断
    • 其他的

第4章2018-2030年分地区市场趋势及预测分析

  • 全球非侵入性癌症诊断市场（按地区）
  • 北美非侵入性癌症诊断市场
  • 欧洲非侵入性癌症诊断市场
  • 亚太非侵入性癌症诊断市场
  • 其他区域非侵入性癌症诊断市场

第5章竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析

第6章成长机会与策略分析

  • 成长机会分析
    • 全球非侵入性癌症诊断与治疗市场的成长机会
    • 全球非侵入性癌症诊断市场的技术成长机会
    • 全球非侵入性癌症诊断市场区域成长机会
  • 全球非侵入性癌症诊断市场的新兴趋势
  • 战略分析
    • 新产品开发
    • 扩大全球非侵入性癌症诊断市场的能力
    • 全球非侵入性癌症诊断市场的合併、收购和合资企业
    • 认证和许可

第7章主要企业概况

  • Precision Therapeutics
  • A&G Pharmaceutical
  • Affymetrix
  • AVIVA Biosciences
  • BIOVIEW
  • Laboratory Corporation of America
  • Quest Diagnostics Incorporated Cancer Genetics
  • Digene
  • Gen-Probe
  • IVDiagnostics
简介目录

Non-Invasive Cancer Diagnostic Trends and Forecast

The future of the global non-invasive cancer diagnostic market looks promising with opportunities in the solid tumors, blood cancer, lung cancer, and breast cancer markets. The global non-invasive cancer diagnostic market is expected to reach an estimated $199.2 billion by 2030 with a CAGR of 6.8% from 2024 to 2030. The major drivers for this market are rising concerns of chronic cancer, introduction of advanced bio marker based detection methods,and supportive government initiative to promote the use of non-invasive diagnostic test.

A more than 150-page report is developed to help in your business decisions.

Non-Invasive Cancer Diagnostic by Segment

The study includes a forecast for the global non-invasive cancer diagnostic by therapeutics, technology, end use industry, technology, and region.

Non-Invasive Cancer Diagnostic Market by Therapeutics [Shipment Analysis by Value from 2018 to 2030]:

  • Solid Tumors
  • Blood Cancer
  • Lung Cancer
  • Breast Cancer
  • Others

Non-Invasive Cancer Diagnostic Market by Technology [Shipment Analysis by Value from 2018 to 2030]:

  • Clinical Chemistry
  • Immunochemistry
  • Molecular Diagnostics
  • Others

Non-Invasive Cancer Diagnostic Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Non-Invasive Cancer Diagnostic Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies non-invasive cancer diagnostic companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the non-invasive cancer diagnostic companies profiled in this report include-

  • Precision Therapeutics
  • A&G Pharmaceutical
  • Affymetrix
  • AVIVA Biosciences
  • BIOVIEW
  • Laboratory Corporation Of America
  • Quest Diagnostics Incorporated Cancer Genetics
  • Digene
  • Gen-Probe
  • IVDiagnostics

Non-Invasive Cancer Diagnostic Market Insights

  • Lucintel forecast that clinical chemistry is expected to witness highest growth over the forecast period due to its various advantages, including highly sensitive, low cost, and widespread availibility.
  • Breast cancer will remain the largest segment due to increasing number of breast cancer patients around the world.
  • North America is expected to witness highest growth over the forecast period due to existence of well-established health infrastructure, growing prevalence of cancer related cases among people, and presence of key players in the region.

Features of the Global Non-Invasive Cancer Diagnostic Market

  • Market Size Estimates: Non-invasive cancer diagnostic market size estimation in terms of value ($B).
  • Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
  • Segmentation Analysis: Non-invasive cancer diagnostic market size by therapeutics, technology, and region. in terms of value ($B).
  • Regional Analysis: Non-invasive cancer diagnostic market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
  • Growth Opportunities: Analysis of growth opportunities in different therapeutics, technology, and region.s for the non-invasive cancer diagnostic market.
  • Strategic Analysis: This includes M&A, new product development, and competitive landscape of the non-invasive cancer diagnostic market.
  • Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1. What is the non-invasive cancer diagnostic market size?

Answer: The global non-invasive cancer diagnostic market is expected to reach an estimated $199.2 billion by 2030.

Q.2. What is the growth forecast for non-invasive cancer diagnostic market?

Answer: The global non-invasive cancer diagnostic market is expected to grow with a CAGR of 6.8% from 2024 to 2030.

Q.3. What are the major drivers influencing the growth of the non-invasive cancer diagnostic market?

Answer: The major drivers for this market are rising concerns of chronic cancer, introduction of advanced bio marker based detection methods, and supportive government initiative to promote the use of non-invasive diagnostic test.

Q.4. What are the major segments for non-invasive cancer diagnostic market?

Answer: The future of the non-invasive cancer diagnostic market looks promising with opportunities in the solid tumors, blood cancer, lung cancer, and breast cancer markets.

Q.5. Who are the key non-invasive cancer diagnostic market companies?

Answer: Some of the key non-invasive cancer diagnostic companies are as follows:

  • Precision Therapeutics
  • A&G Pharmaceutical
  • Affymetrix
  • AVIVA Biosciences
  • BIOVIEW
  • Laboratory Corporation of America
  • Quest Diagnostics Incorporated Cancer Genetics
  • Digene
  • Gen-Probe
  • IVDiagnostics

Q.6. Which non-invasive cancer diagnostic market segment will be the largest in future?

Answer: Lucintel forecast that clinical chemistry is expected to witness highest growth over the forecast period due to its various advantages, including highly sensitive, low cost, and widespread availibility.

Q.7. In non-invasive cancer diagnostic market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness highest growth over the forecast period due to existence of well-established health infrastructure, growing prevalence of cancer related cases among people, and presence of key players in the region.

Q.8. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the non-invasive cancer diagnostic market by therapeutics (solid tumors, blood cancer, lung cancer,breast cancer, and others), technology (clinical chemistry, immunochemistry, molecular diagnostics, and others), and region. (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Non-Invasive Cancer Diagnostic Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Non-Invasive Cancer Diagnostic Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Non-Invasive Cancer Diagnostic Market by Therapeutics
    • 3.3.1: Solid Tumors
    • 3.3.2: Blood Cancer
    • 3.3.3: Lung Cancer
    • 3.3.4: Breast Cancer
    • 3.3.5: Others
  • 3.4: Global Non-Invasive Cancer Diagnostic Market by Technology
    • 3.4.1: Clinical Chemistry
    • 3.4.2: Immunochemistry
    • 3.4.3: Molecular Diagnostics
    • 3.4.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Non-Invasive Cancer Diagnostic Market by Region
  • 4.2: North American Non-Invasive Cancer Diagnostic Market
    • 4.2.1: North American Non-Invasive Cancer Diagnostic Market by Therapeutics : Solid tumors, Blood cancer, Lung Cancer,Breast Cancer,and Others
    • 4.2.2: North American Non-Invasive Cancer Diagnostic Market by Technology:Clinical Chemistry, Immunochemistry, Molecular Diagnostics, and Others
  • 4.3: European Non-Invasive Cancer Diagnostic Market
    • 4.3.1: European Non-Invasive Cancer Diagnostic Market by Therapeutics : Solid tumors, Blood cancer, Lung Cancer,Breast Cancer,and Others
    • 4.3.2: European Non-Invasive Cancer Diagnostic Market by Technology: Clinical Chemistry, Immunochemistry, Molecular Diagnostics, and Others
  • 4.4: APAC Non-Invasive Cancer Diagnostic Market
    • 4.4.1: APAC Non-Invasive Cancer Diagnostic Market by Therapeutics :Solid tumors, Blood cancer, Lung Cancer,Breast Cancer,and Others
    • 4.4.2: APAC Non-Invasive Cancer Diagnostic Market by Technology:Clinical Chemistry, Immunochemistry, Molecular Diagnostics, and Others
  • 4.5: ROW Non-Invasive Cancer Diagnostic Market
    • 4.5.1: ROW Non-Invasive Cancer Diagnostic Market by Therapeutics : Solid tumors, Blood cancer, Lung Cancer,Breast Cancer,and Others
    • 4.5.2: ROW Non-Invasive Cancer Diagnostic Market by Technology: Clinical Chemistry, Immunochemistry, Molecular Diagnostics, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Non-Invasive Cancer Diagnostic Market by Therapeutics
    • 6.1.2: Growth Opportunities for the Global Non-Invasive Cancer Diagnostic Market by Technology
    • 6.1.3: Growth Opportunities for the Global Non-Invasive Cancer Diagnostic Market Region
  • 6.2: Emerging Trends in the Global Non-Invasive Cancer Diagnostic Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Non-Invasive Cancer Diagnostic Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Non-Invasive Cancer Diagnostic Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Precision Therapeutics
  • 7.2: A&G Pharmaceutical
  • 7.3: Affymetrix
  • 7.4: AVIVA Biosciences
  • 7.5: BIOVIEW
  • 7.6: Laboratory Corporation of America
  • 7.7: Quest Diagnostics Incorporated Cancer Genetics
  • 7.8: Digene
  • 7.9: Gen-Probe
  • 7.10: IVDiagnostics